US 12,435,101 B2
Isochroman compound
Zhe Cai, Shanghai (CN); Fei Sun, Shanghai (CN); Charles Z. Ding, Shanghai (CN); and Shuhui Chen, Shanghai (CN)
Assigned to Zhejiang Yangli Pharmaceutical Technology Co., Ltd., Zhejiang (CN)
Appl. No. 18/044,791
Filed by Zhejiang Yangli Pharmaceutical Technology Co., Ltd., Zhejiang (CN)
PCT Filed Sep. 15, 2021, PCT No. PCT/CN2021/118597
§ 371(c)(1), (2) Date Mar. 10, 2023,
PCT Pub. No. WO2022/057838, PCT Pub. Date Mar. 24, 2022.
Claims priority of application No. 202010991814.1 (CN), filed on Sep. 18, 2020.
Prior Publication US 2023/0348503 A1, Nov. 2, 2023
Int. Cl. C07F 9/6558 (2006.01); A61P 35/00 (2006.01)
CPC C07F 9/65586 (2013.01) [A61P 35/00 (2018.01)] 14 Claims
 
1. A compound represented by formula (I) or a pharmaceutically acceptable salt thereof,

OG Complex Work Unit Chemistry
wherein T is N or CH;
R1 and R2 are each independently H, F, Cl, Br, I, or C1-3 alkyl, wherein the C1-3 alkyl is optionally substituted by 1, 2, or 3 Ra;
each Ra is independently F, Cl, Br, I, —CN, —OH or —NH2;
R3 and R4 are each independently H, F, Cl, Br, I, CN, C1-3 alkyl, C1-3 alkoxy,

OG Complex Work Unit Chemistry
wherein the C1-3 alkyl is optionally substituted by 1, 2 or 3 Re;
Rb and Rc are each independently H, —CH3, —CH2CH3, —(CH2)2CH3 or —CH(CH3)2;
Rd is —CH3, —CH2CH3, —(CH2)2CH3 or —CH(CH3)2;
each Re is independently F, Cl, Br, I, —CN, —OH or —NH2.